scholarly journals Propranolol Treatment of Vascular Anomalies Other Than Infantile Hemangioma

2017 ◽  
Vol 225 (4) ◽  
pp. S165
Author(s):  
Jeremy A. Goss ◽  
Dennis J. Konczyk ◽  
Mohammed H. Alomari ◽  
Reid A. Maclellan ◽  
Arin K. Greene
Keyword(s):  
Infantile Hemangioma ◽  
Vascular Anomalies ◽  
Propranolol Treatment

Propranolol Treatment of Vascular Anomalies Other Than Infantile Hemangioma

2017 ◽  
Vol 28 (8) ◽  
pp. 2001-2003 ◽  
Author(s):  
Jeremy A. Goss ◽  
Dennis J. Konczyk ◽  
Mohammed H. Alomari ◽  
Reid A. Maclellan ◽  
Arin K. Greene
Keyword(s):  
Infantile Hemangioma ◽  
Vascular Anomalies ◽  
Propranolol Treatment

scholarly journals Propranolol treatment of infantile subglottic hemangioma: a report of two cases and a literature review

Folia Medica ◽  
2021 ◽  
Vol 63 (4) ◽  
pp. 601-607
Author(s):  
Kalina Ganeva ◽  
Petar Shivachev ◽  
Nikolay Sapundzhiev ◽  
Lora Nikiforova
Keyword(s):  
Literature Review ◽  
Inhaled Corticosteroids ◽  
Previous Treatment ◽  
Infantile Hemangioma ◽  
Benign Tumors ◽  
Close Monitoring ◽  
Upper Respiratory Tract ◽  
Life Threatening ◽  
Propranolol Treatment ◽  
The Subject

Infantile hemangioma is one of the most common benign tumors of infancy. The natural evolution includes rapid growth followed by gradual involution. Airway hemangiomas are not that common, but they can lead to dyspnoea, as well as to life-threatening complications. Two children aged 3 months were admitted to the Pediatric Department with difficulties in breathing and with biphasic stridor. They had previously been hospitalized because of the same symptoms and misdiagnosed as having an upper respiratory tract infection. The previous treatment included intravenous or inhaled corticosteroids, without any significant improvement. Laryngoscopy was performed for both of the children. There was a mass in the subglottic area with the appearance of a hemangioma causing significant airway stenosis. We started treatment with propranolol at a dose of 1 mg/kg/day twice daily. The dose was gradually increased up to 3 mg/kg/day, under close monitoring. In the first 7 to 10 days after initiation of treatment, we observed a significant improvement of the respiratory distress. The second laryngoscopy showed an almost complete involution of the mass in the subglottis.  The focus of this article will be primarily on the clinical presentation and the therapeutic response of subglottic hemangioma, along with a literature review on the subject.

Propranolol treatment of infantile hemangioma is not associated with psychological problems at 7 years of age

2017 ◽  
Vol 77 (1) ◽  
pp. 105-108 ◽  
Author(s):  
Andre Vadimovich Moyakine ◽  
Saskia Spillekom-van Koulil ◽  
Catharina Joanna Maria van der Vleuten
Keyword(s):  
Infantile Hemangioma ◽  
Psychological Problems ◽  
Propranolol Treatment

Propranolol in the Treatment of Problematic Infantile Hemangioma: Review of 35 Consecutive Patients from a Vascular Anomalies Clinic

2012 ◽  
Vol 16 (5) ◽  
pp. 317-323 ◽  
Author(s):  
Janie Bertrand ◽  
Rita Sammour ◽  
Catherine Mccuaig ◽  
JoséE Dubois ◽  
Afshin Hatami ◽  
...  
Keyword(s):  
Retrospective Chart Review ◽  
Infantile Hemangioma ◽  
Oral Solution ◽  
Vascular Anomalies ◽  
Outpatient Basis ◽  
Rapid Improvement ◽  
Nous Croyons ◽  
Β Blocker ◽  
Effet Indésirable ◽  
Oral Propranolol

Background: Propranolol, a nonselective β-blocker, has been reported as efficient for controlling the growth of complicated infantile hemangiomas (IHs). No uniformly accepted protocol exists regarding the administration of oral propranolol for IH. Objective: We sought to share our experience using propranolol for problematic IH and to evaluate the efficacy of this treatment modality. Methods: A retrospective chart review analysis was performed for 35 consecutive children treated with propranolol as an oral solution on an outpatient basis in our dermatology/vascular anomalies clinic. A protocol was established with the help of our pediatric cardiologists, including pretreatment electrocardiography and echocardiography. Medical photographs taken after 2 months of treatment were rated by two independent evaluators. Results: We treated 31 girls and 4 boys with a median age of 3.5 months. Rapid improvement was reported in the first days of treatment in 34 patients. Mean improvement after 2 months was 61.5%. No serious adverse effects were reported. Conclusion: Propranolol was effective in controlling the proliferative phase of problematic IH. It was well tolerated in our study. Outpatient treatment is possible if parents follow strict guidelines. Propranolol should be a first-line treatment for problematic IH in carefully selected patients. Renseignements de base: Le propranolol, un bêta-bloquant non sélectif, s'est révélé efficace pour maîtriser la croissance des hémangiomes infantiles compliqués. On ne dispose pas d'un protocole uniformément accepté quant à l'administration du propranolol oral contre l'hémangiome infantile. Objectif: Nous voulions faire part de notre expérience d'utilisation du propranolol pour traiter les hémangiomes infantiles problématiques et évaluer l'efficacité de cette modalité de traitement. Méthodes: On a exécuté une analyse rétrospective des dossiers de 35 enfants consécutifs qui ont été traités par une solution orale de propranolol de façon ambulatoire dans notre clinique de dermatologie/d'anomalies vasculaires. On a établi un protocole avec l'aide de nos cardiologues pédiatriques, lequel comprenait notamment un ECG et une échographie cardiaque avant le traitement. Les photographies médicales prises après 2 mois de traitement ont été évaluées par deux évaluateurs indépendants. Résultats: Nous avons traité 31 filles et 4 garçons dont l'âge médian était de 3,5 mois. On a signalé, chez 34 patients, une amélioration rapide dès les premiers jours de traitement. L'amélioration moyenne après deux mois s'élevait à 61,5 %. Aucun effet indésirable grave n'a été signalé. Conclusion: Le propranolol était efficace pour maîtriser la phase proliférative de l'hémangiome infantile problématique. Lors de notre étude, il a été bien toléré. Le traitement peut être administré de façon ambulatoire si les parents observent les directives à la lettre. Nous croyons qu'en présence d'un hémangiome infantile problématique, le traitement par le propranolol doit être administré en première intention à des patients soigneusement sélectionnés.

Surgical treatment of infantile hemangioma in a multidisciplinary vascular anomalies clinic

2011 ◽  
Vol 75 (10) ◽  
pp. 1271-1274 ◽  
Author(s):  
Opeyemi O. Daramola ◽  
Robert H. Chun ◽  
John J. Nash ◽  
Beth A. Drolet ◽  
Paula E. North ◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Infantile Hemangioma ◽  
Vascular Anomalies

scholarly journals Infantil Hemangioma and Optimum Dose of Propranolol Treatment: A Retrospective Tertiary-Center Study

2021 ◽  
Author(s):  
Hatice Mine Cakmak ◽  
Omer Kartal
Keyword(s):  
Adverse Event ◽  
Optimal Dose ◽  
Infantile Hemangioma ◽  
Optimum Dose ◽  
Final Dose ◽  
Tertiary Center ◽  
Propranolol Group ◽  
Propranolol Treatment ◽  
Center Study

Abstract Background/Objectives: Propranolol is the mainstay treatment of infantile hemangioma, and the optimal dose is unclear. Few studies are comparing the efficacy of propranolol dose of 2 vs.3 mg/kg/day. We compared the efficacy between these two doses and propranolol groups with no treatment group. Methods: One hundred eight patients with infantile hemangioma (15 days-27 months of age) were examined. The patients with high-risk features and/or a score of >6 points are given propranolol with a final dose of 2 or 3 mg/kg/day according to tolerance for 6-12 months. The resolutions rates for propranolol vs. placebo and propranolol 2 mg/kg/day vs. 3 mg/kg/day are compared. Results: The demographic and clinical features of the groups ( the non-treatment, propranolol 2 mg/kg/day group, propranolol 3 mg/kg/day group) are similar. Propranolol is significantly efficent in infantil hemangioma treatment (p<0.001). The resolution rates are not statistically different between 2 mg/kg/day propranolol group vs 3 mg/kg/day propranolol group at the sixth (68,59 ± 28,95 vs 73,44 ± 32,54)(p=0,673) and twelfth month (p=0,673) (89,08 ± 46,58 vs 91,13 ± 37,46 respectively )of follow up. A milld (n=3)(4%) adverse event was reported with no need for cessation.Conclusions: Propranolol is a safe drug for treating infantile hemangioma with an ideal dose of 2 mg/kg/day rather than 3 mg/kg/day.

Congenital Hepatic Vascular Anomalies

2019 ◽  
Vol 03 (03) ◽  
pp. 184-192
Author(s):  
Rush H. Chewning
Keyword(s):  
Venous Malformation ◽  
Correct Diagnosis ◽  
Delayed Diagnosis ◽  
Infantile Hemangioma ◽  
Epithelioid Hemangioendothelioma ◽  
Vascular Anomalies ◽  
Arterioportal Fistula ◽  
Imaging Characteristics ◽  
Treatment Knowledge ◽  
Congenital Hemangioma

AbstractCongenital hepatic vascular anomalies, following the classification system originally proposed by Mulliken and Glowacki and subsequently developed by the International Society for the Study of Vascular Anomalies, are characterized as either tumors or malformations. The former includes infantile hemangioma, congenital hemangioma, angiosarcoma, and epithelioid hemangioendothelioma. The latter includes arterioportal fistula, portosystemic shunt, arteriovenous malformation, and venous malformation. Despite this well-established system, there still exists confusion in terminology that can lead to delayed diagnosis or improper treatment. Knowledge of the clinical presentation and imaging characteristics of these entities, as well as the nosologic system for vascular anomalies, is essential in arriving at the correct diagnosis, which in turn informs proper treatment.

Propranolol in the Treatment of Problematic Infantile Hemangioma: Review of 35 Consecutive Patients from a Vascular Anomalies Clinic

2012 ◽  
Vol 16 (2) ◽  
pp. 115-121 ◽  
Author(s):  
Janie Bertrand ◽  
Rita Sammour ◽  
Catherine Mccuaig ◽  
Josée Dubois ◽  
Afshin Hatami ◽  
...  
Keyword(s):  
Chart Review ◽  
Retrospective Chart Review ◽  
Infantile Hemangioma ◽  
Oral Solution ◽  
Vascular Anomalies ◽  
Outpatient Basis ◽  
Rapid Improvement ◽  
Review Analysis ◽  
Β Blocker ◽  
Oral Propranolol

Background: Propranolol, a nonselective β-blocker, has been reported as efficient for controlling the growth of complicated infantile hemangiomas (IHs). No uniformly accepted protocol exists regarding the administration of oral propranolol for IH. Objective: We sought to share our experience using propranolol for problematic IH and to evaluate the efficacy of this treatment modality. Methods: A retrospective chart review analysis was performed for 35 consecutive children treated with propranolol as an oral solution on an outpatient basis in our dermatology/vascular anomalies clinic. A protocol was established with the help of our pediatric cardiologists, including pretreatment electrocardiography and echocardiography. Medical photographs taken after 2 months of treatment were rated by two independent evaluators. Results: We treated 31 girls and 4 boys with a median age of 3.5 months. Rapid improvement was reported in the first days of treatment in 34 patients. Mean improvement after 2 months was 61.5%. No serious adverse effects were reported. Conclusion: Propranolol was effective in controlling the proliferative phase of problematic IH. It was well tolerated in our study. Outpatient treatment is possible if parents follow strict guidelines. Propranolol should be a first-line treatment for problematic IH in carefully selected patients.

Sign in / Sign up

Export Citation Format

Share Document